William John Jenkins
Director/Board Member at Apitope Technology (Bristol) Ltd.
Profile
William John Jenkins is an Independent Non-Executive Director at Apitope Technology (Bristol) Ltd.
He is also a Director at AlloCyte Pharmaceuticals AG and BioVersys AG.
Prior to his current positions, he was a Principal at William Jenkins Pharma Consulting.
Jenkins has held various Director and Non-Executive Director positions at companies such as Tanox, Inc., Monogram Biosciences, Inc., Consort Medical Ltd., Eurand NV, BTG Ltd., Ablynx NV, Eurand Pharmaceutical Holdings BV, Apitope International NV, Vaximm AG, Allecra Therapeutics GmbH, and Evotec SE.
He was also the Head of Clinical & Regulatory Affairs at Ciba-Geigy AG and the Head of Clinical Development & Regulatory Affairs at Novartis Pharma AG.
Jenkins received his undergraduate, graduate, and doctorate degrees from the University of Cambridge and a graduate degree from the University of London.
William John Jenkins active positions
Companies | Position | Start |
---|---|---|
William Jenkins Pharma Consulting | Corporate Officer/Principal | 1998-12-31 |
AlloCyte Pharmaceuticals AG
AlloCyte Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology AlloCyte Pharmaceuticals AG develops small molecule drugs for immune-mediated diseases. The private company is based in Basel, Switzerland. | Director/Board Member | - |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Director/Board Member | 2018-03-07 |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Director/Board Member | - |
Former positions of William John Jenkins
Companies | Position | End |
---|---|---|
BTG | Director/Board Member | 2011-02-03 |
Monogram Biosciences, Inc.
Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Director/Board Member | 2009-08-03 |
EVOTEC SE | Director/Board Member | 2007-12-31 |
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Director/Board Member | 2007-08-02 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Chief Tech/Sci/R&D Officer | - |
Training of William John Jenkins
University of Cambridge | Doctorate Degree |
University of London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
EVOTEC SE | Health Technology |
Private companies | 17 |
---|---|
Tanox, Inc.
Tanox, Inc. Pharmaceuticals: MajorHealth Technology Tanox, Inc engages in the discovery and development of therapeutic monoclonal antibodies in the areas of asthma, allergy, inflammation, other diseases affecting the human immune system, and infectious diseases. Its product, Xolair (omalizumab), is used for treatment of adults and adolescents with moderate-to-severe persistent asthma | Health Technology |
Monogram Biosciences, Inc.
Monogram Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Monogram Biosciences, Inc. develops and commercializes diagnostic products for the treatment of human immunodeficiency virus (HIV) infection, hepatitis C virus (HCV) infection, and other viral illnesses, as well as cancer and other diseases. It offers HIV tests, including genotypic, phenotypic, tropism, and combined phenotype and genotype assays, suppression management and viral load testing, HCV assays and oncology tests. The company was founded in 1995 and is headquartered in South San Francisco, CA. | Commercial Services |
Consort Medical Ltd.
Consort Medical Ltd. Pharmaceuticals: MajorHealth Technology Consort Medical Ltd. is a holding company, which engages in pharmaceutical industry related activities. It focuses on the design, development, manufacture, and sale of medical drug and delivery devices. The company was founded on March 22, 1946 and is headquartered in Kings Lynn, the United Kingdom. | Health Technology |
Eurand NV
Eurand NV Pharmaceuticals: MajorHealth Technology Eurand NV develops pharmaceutical and biopharmaceutical products using proprietary drug formulation technologies. The company was founded in 1984 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
BTG Ltd.
BTG Ltd. Pharmaceuticals: MajorHealth Technology BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom. | Health Technology |
Ciba-Geigy AG
Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
Eurand Pharmaceutical Holdings BV | |
Glaxo Group Research Ltd. | |
William Jenkins Pharma Consulting | |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | Health Technology |
AlloCyte Pharmaceuticals AG
AlloCyte Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology AlloCyte Pharmaceuticals AG develops small molecule drugs for immune-mediated diseases. The private company is based in Basel, Switzerland. | Health Technology |
BioVersys AG
BioVersys AG Miscellaneous Commercial ServicesCommercial Services BioVersys AG operates as a holding company, which specializes in the research and development of small molecules acting on novel bacterial targets. Its research focuses on nosocomial infection and tuberculosis. The company was founded by Marc Gitzinger and Marcel Tigges on September 24, 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
Vaximm AG
Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- William John Jenkins